PITTSBURGH, Aug 27, 2009 /PRNewswire-FirstCall via COMTEX/ ----Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of Sanofi Aventis' BenzaClin(R) to be approved by the U.S. Food and Drug Administration (FDA).

On Aug. 11, Dow received FDA approval for its Abbreviated New Drug Application (ANDA) for Clindamycin 1% and Benzoyl Peroxide 5% Gel, a prescription-strength topical antibiotic used to treat acne. According to IMS Health, BenzaClin had total U.S. sales of approximately $221 million for the 12 months ending June 30.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

http://www.mylan.com
   

Copyright (C) 2009 PR Newswire. All rights reserved
   
   **********************************************************************
   
   As of Sunday, 08-23-2009 23:59, the latest Comtex SmarTrend� Alert, 
   an automated pattern recognition system, indicated an UPTREND on 
   12-08-2008 for RX @ $13.86.
   
   As of Sunday, 08-23-2009 23:59, the latest Comtex SmarTrend Alert, 
   an automated pattern recognition system, indicated an UPTREND on 
   12-03-2008 for VRX @ $20.10.
   
   For more information on SmarTrend, contact your market data
   provider or go to www.mysmartrend.com
   
   SmarTrend is a registered trademark of Comtex News Network, Inc.
   Copyright � 2004-2009 Comtex News Network, Inc. All rights reserved.